Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Target Lowered at TD Cowen

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price cut by TD Cowen from $482.00 to $354.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen‘s price objective would suggest a potential upside of 111.25% from the stock’s current price.

A number of other brokerages have also recently issued reports on ALNY. Sanford C. Bernstein cut shares of Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $376.00 to $199.00 in a research note on Friday. HC Wainwright reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday. Barclays reduced their price target on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a research report on Monday, August 3rd. Royal Bank Of Canada decreased their price objective on shares of Alnylam Pharmaceuticals from $345.00 to $280.00 and set an “outperform” rating for the company in a report on Friday. Finally, Morgan Stanley cut their target price on Alnylam Pharmaceuticals from $300.00 to $240.00 and set an “equal weight” rating on the stock in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $326.74.

Alnylam Pharmaceuticals Stock Down 3.7%

NASDAQ:ALNY traded down $6.42 during trading hours on Friday, reaching $167.57. 3,646,012 shares of the company traded hands, compared to its average volume of 1,501,960. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The business’s 50-day moving average price is $237.78 and its two-hundred day moving average price is $287.22. Alnylam Pharmaceuticals has a 1 year low of $167.16 and a 1 year high of $479.79. The stock has a market capitalization of $22.42 billion, a P/E ratio of 31.13 and a beta of 0.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The firm had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same period in the prior year, the firm posted $2.90 earnings per share. The company’s quarterly revenue was up 16.7% on a year-over-year basis. Analysts predict that Alnylam Pharmaceuticals will post 6.43 earnings per share for the current year.

Insider Activity

In other news, EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the sale, the executive vice president owned 12,807 shares of the company’s stock, valued at $2,905,652.16. This represents a 12.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. SCS Capital Management LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $34,784,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $50,773,000. Silvant Capital Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $5,456,000. WINTON GROUP Ltd bought a new stake in Alnylam Pharmaceuticals during the second quarter valued at about $2,372,000. Finally, Wealthfront Advisers LLC purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $2,876,000. 92.97% of the stock is currently owned by institutional investors.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q3 results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, ahead of estimates. The company maintained its fiscal 2026 net product-sales outlook. Alnylam Q3 earnings and revenue results
• Positive Sentiment: Long-term pipeline prospects remain supportive. Alnylam expects $4.2 billion-$4.5 billion in 2026 TTR sales and expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an expected launch timeline around 2030. Alnylam TTR sales and TRITON-CM update
• Neutral Sentiment: Analysts remain divided. Wells Fargo lowered its target to $220 and kept an “equal weight” rating; RBC cut its target to $280 but retained “outperform”; and Needham reduced its target to $243 while maintaining “buy.” These targets still imply substantial potential upside from recent levels.
• Negative Sentiment: Demand growth is the immediate concern. Slower U.S. Amvuttra patient starts and moderating Amvuttra and Onpattro sales growth raised questions about the pace of commercial expansion despite the quarterly beat. Alnylam demand growth concerns
• Negative Sentiment: Broker sentiment weakened. Bernstein downgraded Alnylam to “market perform” with a $199 target, while Stifel cut its rating to “hold” and set a $225 target. The reductions reflect greater caution around near-term growth and valuation.
• Negative Sentiment: Additional risk overhangs remain. An investor law firm announced an investigation related to a prior company disclosure, potentially adding to market uncertainty, although no wrongdoing has been established. Alnylam investor investigation

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.